183 related articles for article (PubMed ID: 20506157)
21. Nitric oxide regulates receptor activator of nuclear factor-kappaB ligand and osteoprotegerin expression in bone marrow stromal cells.
Fan X; Roy E; Zhu L; Murphy TC; Ackert-Bicknell C; Hart CM; Rosen C; Nanes MS; Rubin J
Endocrinology; 2004 Feb; 145(2):751-9. PubMed ID: 14563699
[TBL] [Abstract][Full Text] [Related]
22. RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma.
Roux S; Meignin V; Quillard J; Meduri G; Guiochon-Mantel A; Fermand JP; Milgrom E; Mariette X
Br J Haematol; 2002 Apr; 117(1):86-92. PubMed ID: 11918537
[TBL] [Abstract][Full Text] [Related]
23. Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation.
Lai FP; Cole-Sinclair M; Cheng WJ; Quinn JM; Gillespie MT; Sentry JW; Schneider HG
Br J Haematol; 2004 Jul; 126(2):192-201. PubMed ID: 15238139
[TBL] [Abstract][Full Text] [Related]
24. Hyaluronan increases RANKL expression in bone marrow stromal cells through CD44.
Cao JJ; Singleton PA; Majumdar S; Boudignon B; Burghardt A; Kurimoto P; Wronski TJ; Bourguignon LY; Halloran BP
J Bone Miner Res; 2005 Jan; 20(1):30-40. PubMed ID: 15619667
[TBL] [Abstract][Full Text] [Related]
25. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
26. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway.
Tsai HY; Lin HY; Fong YC; Wu JB; Chen YF; Tsuzuki M; Tang CH
Eur J Pharmacol; 2008 Jun; 588(1):124-33. PubMed ID: 18495114
[TBL] [Abstract][Full Text] [Related]
27. The novel isoflavone derivatives inhibit RANKL-induced osteoclast formation.
Tang CH; Chang CS; Tan TW; Liu SC; Liu JF
Eur J Pharmacol; 2010 Dec; 648(1-3):59-66. PubMed ID: 20850430
[TBL] [Abstract][Full Text] [Related]
28. Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency.
Kanematsu M; Sato T; Takai H; Watanabe K; Ikeda K; Yamada Y
J Bone Miner Res; 2000 Jul; 15(7):1321-9. PubMed ID: 10893680
[TBL] [Abstract][Full Text] [Related]
29. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production.
Lee SK; Gardner AE; Kalinowski JF; Jastrzebski SL; Lorenzo JA
Bone; 2006 May; 38(5):678-85. PubMed ID: 16309985
[TBL] [Abstract][Full Text] [Related]
30. Role of p38 in regulation of hematopoiesis: effect of p38 inhibition on cytokine production and transcription factor activity in human bone marrow stromal cells.
Scicchitano MS; McFarland DC; Tierney LA; Boyce RW; Frazier KS; Schwartz LW; Thomas HC
Blood Cells Mol Dis; 2008; 40(3):370-80. PubMed ID: 18093851
[TBL] [Abstract][Full Text] [Related]
31. Involvement of integrin up-regulation in RANKL/RANK pathway of chondrosarcomas migration.
Hsu CJ; Lin TY; Kuo CC; Tsai CH; Lin MZ; Hsu HC; Fong YC; Tang CH
J Cell Biochem; 2010 Sep; 111(1):138-47. PubMed ID: 20506523
[TBL] [Abstract][Full Text] [Related]
32. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T
Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286
[TBL] [Abstract][Full Text] [Related]
33. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
34. Risedronate inhibits bone marrow mesenchymal stem cell adipogenesis and switches RANKL/OPG ratio to impair osteoclast differentiation.
Jin J; Wang L; Wang XK; Lai PL; Huang MJ; Jin DD; Zhong ZM; Chen JT; Bai XC
J Surg Res; 2013 Mar; 180(1):e21-9. PubMed ID: 22487394
[TBL] [Abstract][Full Text] [Related]
35. Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone.
Menaa C; Reddy SV; Kurihara N; Maeda H; Anderson D; Cundy T; Cornish J; Singer FR; Bruder JM; Roodman GD
J Clin Invest; 2000 Jun; 105(12):1833-8. PubMed ID: 10862799
[TBL] [Abstract][Full Text] [Related]
36. Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients.
Wallace SR; Oken MM; Lunetta KL; Panoskaltsis-Mortari A; Masellis AM
Cancer; 2001 Apr; 91(7):1219-30. PubMed ID: 11283920
[TBL] [Abstract][Full Text] [Related]
37. Extracellular inorganic phosphate regulates gibbon ape leukemia virus receptor-2/phosphate transporter mRNA expression in rat bone marrow stromal cells.
Wada K; Mizuno M; Komori T; Tamura M
J Cell Physiol; 2004 Jan; 198(1):40-7. PubMed ID: 14584042
[TBL] [Abstract][Full Text] [Related]
38. Disparate osteogenic response of mandible and iliac crest bone marrow stromal cells to pamidronate.
Stefanik D; Sarin J; Lam T; Levin L; Leboy PS; Akintoye SO
Oral Dis; 2008 Jul; 14(5):465-71. PubMed ID: 18938273
[TBL] [Abstract][Full Text] [Related]
39. Dominant negative N-cadherin inhibits osteoclast differentiation by interfering with beta-catenin regulation of RANKL, independent of cell-cell adhesion.
Shin CS; Her SJ; Kim JA; Kim DH; Kim SW; Kim SY; Kim HS; Park KH; Kim JG; Kitazawa R; Cheng SL; Civitelli R
J Bone Miner Res; 2005 Dec; 20(12):2200-12. PubMed ID: 16294273
[TBL] [Abstract][Full Text] [Related]
40. [Effects of the osteoclast in pathogenesis of multiple myeloma].
Zhang JH; Fu JX; Zhang XH; Sun Y
Zhonghua Xue Ye Xue Za Zhi; 2007 May; 28(5):323-6. PubMed ID: 17877161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
